Non-alcoholic fatty liver disease (NAFLD) is a condition in which fat builds up in the liver. There are two types of NAFLD, simple fatty liver and non-alcoholic steatohepatitis (NASH). No complications or liver cell damage occur in patients with the simple fatty liver. NASH is associated with liver cell damage and inflammation that causes scarring or fibrosis, leading to liver cancer. The complications associated with NAFLD are liver failure, cardiovascular disease, and liver cancer. The symptoms observed in patients with NAFLD are nausea, loss of appetite, yellowing of skin and eyes, swelling of legs (leg edema), itching, and abdominal pain. Zydus Discovery DMCC is in the process of developing saroglitazar as a peroxisome proliferator-activated receptor alpha agonist for the treatment of NAFLD. University of California, San Diego is in the process of developing aramchol as a ATP binding cassette transporter I stimulant for the treatment of NAFLD. Some of the companies having the pipeline of NAFLD include AstraZeneca plc, Kowa Company, Ltd., Viking Therapeutics, Inc., and others.
The report provides a comprehensive understanding of the pipeline activities covering all drug candidates under various stages of development, with the detailed analysis of pipeline and clinical trials. Pipeline analysis of drugs by phases includes product description and development activities including information about clinical results, designations, collaborations, licensing, grants, technology, and others.